A combination pill from Myovant Sciences met its primary goal of reducing pain from endometriosis, the biotech company said Tuesday, the second late-stage trial to show the drug’s effectiveness in women with the condition.
Myovant (MYOV), a biotech based in Switzerland with U.S. operations in Brisbane, Calif., has also been testing the hormone blocker, called relugolix, as a treatment for uterine fibroids and advanced prostate cancer. On Monday, the company received a priority review of relugolix for advanced prostate cancer from the Food and Drug Administration, meaning the agency will expedite its decision on whether to approve the drug for these patients. A study comparing standard injected therapy to the oral relugolix, published in the New England Journal of Medicine on June 4, showed better outcomes for men who took relugolix.
About the Author Reprints
